PRESS RELEASE RENOLIT KUMOVIS series A funding
RENOLIT became strategic partner of KUMOVIS which closed series A funding
KUMOVIS, a 3D printing system developer to enter new markets, accelerates growth, and enables medical device manufacturers to tap the full potential of high-performance polymers
Worms – May 28 2020 – RENOLIT announced today its participation in the serie A funding round of the Munich-based start-up KUMOVIS, the developer of the world’s first unique 3D printer integrated in a clean room integration, together with SOLVAY and the two seed investors the High-Tech Gründerfonds and Ffilipa Venture Capital. RENOLIT became as such the unique strategic healthcare investor of KUMOVIS.
“This investment is a further major step for RENOLIT Healthcare fostering its innovative dynamics towards health together with partners, by reinforcing its presence in polymer based healthcare devices with new innovative technologies and devices, as well as new business models”, confirms Thomas Sampers heading RENOLIT Healthcare.
“The launch of the Kumovis R1 3D printer in 2019 pushed additive manufacturing with medical polymers to the next level regarding mechanical properties, aesthetic, reproducibility and usability. We are convinced that partnership with RENOLIT, leader in polymer based medical device components, will strengthen our business case and accelerate the development of Kumovis. The investment will be used to enter new markets, further develop our technology and help to bring 3D printed medical products to the patient”, said Stefan Leonhardt, co-CEO and co-founder of KUMOVIS.
Create decentralized manufacturing capacities
“The flexibility of our 3D printing system, which fulfills all medical manufacturing requirements, is particularly advantageous when it comes to small-series production or patient-individualized products. Thanks to the technology, production can be located at optimal location along the value chain, and in particular right at point of care. This allows the shortening of the supply chain and thus also the time to patient”, adds Dr. Miriam Haerst, also co-CEO and co-founder of Kumovis.
“I am looking forward to support the young talented dynamic team of KUMOVIS which I am convinced will benefit of the expertise and competences of RENOLIT in Healthcare”, concludes Pierre Winant, RENOLIT representative in the Board of Directors of the start-up.
About RENOLIT SE
The RENOLIT Group is a globally active specialist for high performance polymer films, sheets and other plastic products. With more than thirty sites and sales units in over twenty countries, and with annual sales of EUR 1,059 billion in fiscal year 2019, the company with headquarters in Worms – around 70 km South of Frankfurt-am-Main – is one of the world’s leading plastics product manufacturers. More than 4,800 employees continue to further developing the knowledge and expertise gained from over seventy years of business.
Horchheimer Straße, 50
67547 – Worms